Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Cancer Genetics Inc (CGIX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 22,894
  • Shares Outstanding, K 27,750
  • Annual Sales, $ 29,120 K
  • Annual Income, $ -20,880 K
  • 36-Month Beta 0.53
  • Price/Sales 0.82
  • Price/Cash Flow N/A
  • Price/Book 1.38
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.80
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/08/18
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -0.16
  • Number of Estimates 1
  • High Estimate -0.16
  • Low Estimate -0.16
  • Prior Year -0.16
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.80 +8.75%
on 10/15/18
1.25 -30.40%
on 09/26/18
-0.39 (-30.95%)
since 09/21/18
3-Month
0.80 +8.75%
on 10/15/18
1.30 -33.08%
on 09/21/18
-0.06 (-6.45%)
since 07/20/18
52-Week
0.80 +8.75%
on 10/15/18
3.50 -75.14%
on 10/31/17
-1.88 (-68.36%)
since 10/20/17

Most Recent Stories

More News
Cancer Genetics Enters Strategic Partnership with Genecast Biotechnology to Commercialize Tissue of Origin(R) Test in China

Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomics through molecular markers and diagnostics, today announced that it has signed an exclusive...

CGIX : 0.87 (+5.45%)
Cancer Genetics Issues Letter to Shareholders

Cancer Genetics (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomics through molecular markers and diagnostics, today announced the publication of a letter to shareholders...

CGIX : 0.87 (+5.45%)
Cancer Genetics and Cellaria Partner on Precision Medicine Tools

Cancer Genetics (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomics through molecular markers and diagnostics, and Cellaria, LLC, a scientific innovator that develops...

CGIX : 0.87 (+5.45%)
Robbins Arroyo LLP: Cancer Genetics, Inc. (CGIX) Sued by Shareholders in Recently Filed Class Action

Shareholder rights law firm Robbins Arroyo LLP announces that purchasers of Cancer Genetics, Inc. (NASDAQ: CGIX) have filed a class action complaint against the company's officers...

CGIX : 0.87 (+5.45%)
Cancer Genetics Offers Oncomine Comprehensive Assay to Drive Clinical Trials

Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomics through molecular markers and diagnostics, today announced the successful CLIA validation...

CGIX : 0.87 (+5.45%)
Chardan Advises NovellusDX in Cross-Border Biotech Merger

Chardan, a global investment bank, announced today that the firm acted as exclusive financial advisor to NovellusDX, Ltd., a leader in functional genomics, for the firm's agreement to merge with a newly...

CGIX : 0.87 (+5.45%)
Cancer Genetics and NovellusDx Sign Definitive Agreement to Merge

Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular markers and diagnostics, and NovellusDx, Ltd., a leader in functional...

CGIX : 0.87 (+5.45%)
Cancer Genetics Reports Second Quarter 2018 Financial Results and Provides Strategic Business Updates

Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular markers and diagnostics, today announced financial and operating...

CGIX : 0.87 (+5.45%)
Cancer Genetics, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / August 14, 2018 / Cancer Genetics, Inc. (NASDAQ: ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 14, 2018 at 8:30 AM Eastern Time....

CGIX : 0.87 (+5.45%)
Cancer Genetics to Report Second Quarter 2018 Financial Results on August 14, 2018

Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, today announced that it will release its financial results for the...

CGIX : 0.87 (+5.45%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators mostly agree with the trend.

See More Share

Trade CGIX with:

Business Summary

Cancer Genetics, Inc. operates as a diagnostics company focused on developing and commercializing proprietary genomic tests and services to improve the diagnosis, prognosis and response to treatment of cancer. The company's tests target cancers, including hematological, urogenital, and HPV-associated...

See More

Key Turning Points

2nd Resistance Point 0.94
1st Resistance Point 0.90
Last Price 0.87
1st Support Level 0.83
2nd Support Level 0.80

See More

52-Week High 3.50
Fibonacci 61.8% 2.47
Fibonacci 50% 2.15
Fibonacci 38.2% 1.83
Last Price 0.87
52-Week Low 0.80

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar